Stocks Health care TECX
NASDAQ · Health careTectonic Therapeutic, Inc. (TECX)
It posted a net loss of $85.8M. In fiscal 2025 capital spending exceeded operating cash flow by $60.3M. At June 30, 2026 it held $227.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Tectonic Therapeutic, Inc. does
Tectonic Therapeutic, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TECX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$74.2M | -$4.05 | -$60.3M |
| 2024 | n/a | -$58M | -$6.83 | -$59.2M |
| 2023 | n/a | -$42.8M | -$33.76 | -$41M |
| 2022 | n/a | -$105.9M | -$2.42 | -$97.5M |
| 2021 | n/a | -$119.1M | -$2.78 | -$100.5M |
| 2020 | n/a | -$119.7M | -$3.31 | -$100M |
Latest SEC filings
What Tectonic Therapeutic, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 10, 2026
- May 7, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- April 24, 2026
- April 24, 2026Additional proxy material DEFA14A
- April 24, 2026Proxy statement DEF 14A
- April 23, 2026
- March 9, 2026Form S-8 POS filing S-8 POS
Insider trades
What the people running Tectonic Therapeutic, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.6K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 25, 2026 | McNamara PeterChief Scientific Officer | Exercised options | 43 | $632.5 |
| August 25, 2026 | McNamara PeterChief Scientific Officer | Soldpre-planned (10b5-1) | 43 | $1.6K |
Questions about TECX
What does Tectonic Therapeutic, Inc. do?
Tectonic Therapeutic, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TECX.
Is Tectonic Therapeutic, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $85.8M.
When did Tectonic Therapeutic, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 8, 2026.
Similar companies
Compare TECX with
Follow TECX
Get an email when Tectonic Therapeutic, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TECX: get an email when it filesWhere the numbers come from
Financial figures are the values Tectonic Therapeutic, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.